Here are the 424B prospectus supplements from Sunshine Biopharma Inc. warrant (SBFMW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SBFMW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBFMW filings page.
Sunshine Biopharma Inc. is initiating an at-the-market common stock offering of up to $4,000,000 under a Sales Agreement with Aegis Capital Corp., acting as exclusive sales agent. Shares may be sold from time to time on Nasdaq as defined in Rule 415.
The company will pay Aegis a 3.0% cash commission on gross proceeds and reimburse specified expenses, and Aegis will be deemed an underwriter. Net proceeds are intended for general corporate purposes, including working capital. Under General Instruction I.B.6 of Form S-3, primary offerings are limited to one-third of non-affiliate market value while it remains below $75 million.